https://www.asannslab.com/news/risk-of-major-congenital-malformations-and-exposure-to-antiseizure-medication-monotherapy 2024-11-21 https://www.asannslab.com/news/sublingual-edaravone-dexborneol-for-the-treatment-of-acute--ischemic-stroke%3A--the-taste-sl-randomized-clinical-trial 2024-11-21 https://www.asannslab.com/news/automated-interpretation-of-clinical-electroencephalograms-using-artificial-intelligence 2024-11-20 https://www.asannslab.com/news/reversal-of-imaging-findings-of-idiopathic-intracranial-hypertension-after-lumbar-puncture- 2024-11-21 https://www.asannslab.com/news/risk-of-inflammatory-central-nervous-system-diseases-after-tumor-necrosis-factor%E2%80%93inhibitor-treatment-for-autoimmune-diseasesa-systematic-review-and-meta-analysis-- 2024-11-21 https://www.asannslab.com/news/development-and-validation-of-a-clinical-score-to-predict-epilepsy-after-cerebral-venous-thrombosis- 2024-11-20 https://www.asannslab.com/news/tenecteplase-for-ischemic-stroke-at-4.5-to-24-hours-without-thrombectomy- 2024-11-21 https://www.asannslab.com/news/restrictive-vs-liberal-transfusion-strategy-in-patients-with-acute-brain-injury-the-train-randomized-clinical-trial 2024-11-21 https://www.asannslab.com/news/liberal-or-restrictive-transfusion-strategy-in-patients-with-traumatic-brain-injury 2024-11-20 https://www.asannslab.com/news/adjunctive-intravenous-argatroban-or-eptifibatide-for-ischemic-stroke 2024-11-20 https://www.asannslab.com/news/medical-management-and-surgery-versus-medical-management-alone 2024-11-20 https://www.asannslab.com/news/endovascular-thrombectomy 2024-11-20 https://www.asannslab.com/news/intracranial-pressure-monitoring 2024-11-20 https://www.asannslab.com/news/apixabanvsaspirin 2024-11-20